Driver gene mutations among non-small cell lung cancer tissues and its clinical significance
10.13315/j.cnki.cjcep.2017.11.002
- VernacularTitle:非小细胞肺癌患者肿瘤组织多驱动基因联合检测及其临床意义
- Author:
Chang-Shao YANG
1
;
Yan-Long YANG
;
Xiao-Jie DING
;
Ya-Xi DU
;
Quan LI
;
Yin-Jin GUO
;
Jun-Xi LIU
;
Yong-Chun ZHOU
Author Information
1. 云南省肿瘤医院肿瘤研究所/云南省肺癌研究重点实验室
- Keywords:
lung neoplasm;
non-small cell lung cancer;
EGFR;
KRAS;
ALK;
ROS1
- From:
Chinese Journal of Clinical and Experimental Pathology
2017;33(11):1183-1187
- CountryChina
- Language:Chinese
-
Abstract:
Purpose To investigate the mutation rate of EGFR,KRAS,ALK and ROS1 in non-small cell lung cancer (NSCLC) and its association with clinical or pathological characteristics.Methods 86 NSCLC tissues were included.Fluorescence PCR was used to detect the EGFR,KRAS mutation and ALK,ROS1 fusion gene.The association between EGFR,KRAS,ALK and ROS1 gene and age,gender,smoking history,histological type,lymph node metastasis and other clinical pathological features were analyzed.Results The total mutation rate of the driver gene in NSCLC patients was 62.8％ (54/86).EGFR mutation rate was 76％ (41/54).KRAS mutation rate was 9.3％ (5/54).ALK gene fusion mutation rate was 13.0％ (7/54),and in one of the patients,EGFR 19 deletion mutation and ALK fusion co-exist.ROS1 gene fusion mutation was 3.8％ (2/54).EGFR gene mutation rate was higher in adenocarcinoma and female (P ＜ 0.05),but no significant association was found in age,smoking history and lymph node metastasis (P ＞0.05).KRAS,ALK,ROS1 genes had no obvious correlation with clinical pathological features (P ＞ 0.05).Conclusion The EGFR mutation and ALK fusion was rather high in patients with NSCLC.More attention should be paid to them.Though KRAS,ROS1 mutations and double mutations were low in NSCLC patients,they should not be ignored.
